ZimVie (ZIMV) Competitors $18.88 +0.03 (+0.13%) As of 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZIMV vs. EYE, LMAT, CNMD, LQDA, ENOV, AORT, CDRE, NVCR, SSII, and ESTAShould you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include National Vision (EYE), LeMaitre Vascular (LMAT), CONMED (CNMD), Liquidia Technologies (LQDA), Enovis (ENOV), Artivion (AORT), Cadre (CDRE), NovoCure (NVCR), SS Innovations International (SSII), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry. ZimVie vs. Its Competitors National Vision LeMaitre Vascular CONMED Liquidia Technologies Enovis Artivion Cadre NovoCure SS Innovations International Establishment Labs National Vision (NASDAQ:EYE) and ZimVie (NASDAQ:ZIMV) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Is EYE or ZIMV more profitable? National Vision has a net margin of -0.75% compared to ZimVie's net margin of -4.39%. ZimVie's return on equity of 6.37% beat National Vision's return on equity.Company Net Margins Return on Equity Return on Assets National Vision-0.75% 3.56% 1.49% ZimVie -4.39%6.37%3.34% Does the media favor EYE or ZIMV? In the previous week, National Vision had 15 more articles in the media than ZimVie. MarketBeat recorded 16 mentions for National Vision and 1 mentions for ZimVie. ZimVie's average media sentiment score of 1.87 beat National Vision's score of 1.02 indicating that ZimVie is being referred to more favorably in the news media. Company Overall Sentiment National Vision Positive ZimVie Very Positive Do analysts rate EYE or ZIMV? National Vision currently has a consensus target price of $24.73, suggesting a potential upside of 5.44%. ZimVie has a consensus target price of $17.75, suggesting a potential downside of 5.96%. Given National Vision's stronger consensus rating and higher possible upside, equities research analysts plainly believe National Vision is more favorable than ZimVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score National Vision 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60ZimVie 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, EYE or ZIMV? National Vision has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, ZimVie has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Do institutionals and insiders hold more shares of EYE or ZIMV? 95.6% of ZimVie shares are owned by institutional investors. 2.7% of National Vision shares are owned by company insiders. Comparatively, 5.4% of ZimVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable valuation & earnings, EYE or ZIMV? ZimVie has lower revenue, but higher earnings than National Vision. National Vision is trading at a lower price-to-earnings ratio than ZimVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNational Vision$1.89B0.99-$28.50M-$0.18-130.29ZimVie$449.75M1.18-$25.83M-$0.70-26.96 SummaryZimVie beats National Vision on 9 of the 16 factors compared between the two stocks. Get ZimVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZIMV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIMV vs. The Competition Export to ExcelMetricZimVieMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$532.28M$10.64B$5.63B$9.80BDividend YieldN/A2.00%4.64%4.14%P/E Ratio-26.9620.4130.2025.63Price / Sales1.1824.34463.44105.91Price / Cash10.1423.7337.7258.50Price / Book1.293.088.456.05Net Income-$25.83M$211.77M$3.26B$265.11M7 Day Performance0.29%8.32%3.22%2.54%1 Month Performance109.72%9.24%5.66%3.63%1 Year Performance11.62%-6.52%42.67%26.29% ZimVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIMVZimVie0.9581 of 5 stars$18.88+0.1%$17.75-6.0%+7.7%$532.28M$449.75M-26.961,770Positive NewsEYENational Vision2.8831 of 5 stars$25.07+3.6%$24.18-3.5%+123.2%$1.91B$1.82B-75.9713,411Positive NewsEarnings ReportLMATLeMaitre Vascular2.1918 of 5 stars$84.36+4.1%$97.83+16.0%+15.0%$1.83B$226.26M42.61490Insider TradeCNMDCONMED3.9498 of 5 stars$53.46+2.2%$59.80+11.9%-18.1%$1.62B$1.31B15.153,900Dividend AnnouncementLQDALiquidia Technologies2.9771 of 5 stars$19.48+10.2%$26.89+38.0%+97.4%$1.51B$14M-12.3350Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap UpENOVEnovis3.865 of 5 stars$26.61+3.4%$55.60+109.0%-32.2%$1.47B$2.11B-1.917,367News CoverageEarnings ReportAnalyst RevisionAORTArtivion2.9634 of 5 stars$32.06+3.7%$32.40+1.1%+73.9%$1.32B$388.54M-64.121,600Earnings ReportAnalyst DowngradeCDRECadre3.7938 of 5 stars$33.09+2.3%$37.50+13.3%-12.7%$1.31B$567.56M34.832,284News CoverageAnalyst DowngradeAnalyst RevisionGap DownNVCRNovoCure4.578 of 5 stars$11.76+3.9%$28.79+144.8%-38.3%$1.27B$605.22M-7.541,488Positive NewsSSIISS Innovations InternationalN/A$6.57+6.0%N/AN/A$1.20B$20.65M0.004Gap UpESTAEstablishment Labs2.0933 of 5 stars$42.72+3.3%$54.83+28.4%-18.1%$1.20B$166.02M-13.781,018Earnings Report Related Companies and Tools Related Companies National Vision Competitors LeMaitre Vascular Competitors CONMED Competitors Liquidia Technologies Competitors Enovis Competitors Artivion Competitors Cadre Competitors NovoCure Competitors SS Innovations International Competitors Establishment Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIMV) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZimVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZimVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.